Trial Profile
A Phase Ib Trial of Neoadjuvant Durvalumab (MEDI4736) +/- Tremelimumab in Locally Advanced Renal Cell Carcinoma
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Durvalumab (Primary) ; Tremelimumab (Primary)
- Indications Renal cell carcinoma
- Focus Adverse reactions
- 21 Dec 2020 Status changed from suspended to completed.
- 31 May 2020 Results presented at the 56th Annual Meeting of the American Society of Clinical Oncology
- 31 May 2020 Status changed from active, no longer recruiting to suspended as per the results presented at the 56th Annual Meeting of the American Society of Clinical Oncology.